52-Week results from IXORA-S: a randomized head-to-head trial of ixekizumab and ustekinumab in patients with moderate-to-severe plaque psoriasis

被引：0
|
作者：
Paul, C. [1 ]
van de Kerkhof, P. [2 ]
Dutronc, Y. [3 ]
Henneges, C. [3 ]
Dossenbach, M. [3 ]
Hollister, K. [3 ]
Reich, K. [4 ,5 ]
机构：
[1] Paul Sabatier Univ, CHU, Dermatol, Toulouse, France
[2] Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, Nijmegen, Netherlands
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Dermatol Hamburg, Hamburg, Germany
[5] SCIderm Res Inst, Hamburg, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2017年 / 177卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P094
引用
收藏
页码：E293 / E293
页数：1
相关论文
共 50 条
  • [31] Consistency of response across subgroups of patients with moderate-to-severe plaque psoriasis following 52 weeks of treatment with ixekizumab compared to ustekinumab
    Paul, C.
    Puig, L.
    Dutronc, Y.
    Henneges, C.
    Reich, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S81 - S81
  • [32] Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
    Yoshinori Umezawa
    Akihiko Asahina
    Shinichi Imafuku
    Yayoi Tada
    Shigetoshi Sano
    Akimichi Morita
    Shinya Sakurai
    Naoki Hoshii
    Nicola Tilt
    Hidemi Nakagawa
    Dermatology and Therapy, 2021, 11 : 943 - 960
  • [33] Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
    Umezawa, Yoshinori
    Asahina, Akihiko
    Imafuku, Shinichi
    Tada, Yayoi
    Sano, Shigetoshi
    Morita, Akimichi
    Sakurai, Shinya
    Hoshii, Naoki
    Tilt, Nicola
    Nakagawa, Hidemi
    DERMATOLOGY AND THERAPY, 2021, 11 (03) : 943 - 960
  • [34] Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study
    Gottlieb, A. B.
    Merola, J. F.
    Reich, K.
    Behrens, F.
    Nash, P.
    Griffiths, C. E. M.
    Bao, W.
    Pellet, P.
    Pricop, L.
    McInnes, I. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (06) : 1124 - 1134
  • [35] Comparison of Ixekizumab and Ustekinumab Efficacy in the Treatment of Nail Lesions of Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Data from a Phase 3 Trial
    Ghislain, Pierre-Dominique
    Conrad, Curdin
    Dutronc, Yves
    Henneges, Carsten
    Calderon, David Sandoval
    Vincent, Myriam
    Ghys, Liesbet
    de Gruijter, Jolien
    van de Kerkhof, Peter C. M.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [36] Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis
    Teeple, Amanda
    Muser, Erik
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (12) : 1268 - 1273
  • [37] Efficacy and safety of infliximab biosimilar in the treatment of moderate-to-severe plaque psoriasis: A 52-week clinical study
    Panagakis, Pantelis
    Rompoti, Natalia
    Stravodimou, Aristea
    Papoutsaki, Marina
    Rigopoulos, Dimitrios
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB198 - AB198
  • [38] Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
    Dauden, Esteban
    de la Cueva, Pablo
    Salgado-Boquete, Laura
    Llamas-Velasco, Mar
    Fonseca, Eduardo
    Pau-Charles, Ignasi
    Asensio, David
    Guila, Meritxell
    Manuel Carrascosa, Jose
    DERMATOLOGY AND THERAPY, 2023, 13 (01) : 329 - 345
  • [39] Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
    Esteban Daudén
    Pablo de la Cueva
    Laura Salgado-Boquete
    Mar Llamas-Velasco
    Eduardo Fonseca
    Ignasi Pau-Charles
    David Asensio
    Meritxell Guilà
    José Manuel Carrascosa
    Dermatology and Therapy, 2023, 13 : 329 - 345
  • [40] Sustained and rapid improvements in patient reported outcomes for moderate-to-severe psoriasis patients with moderate and high BSA treated with ixekizumab: Side-by-side results from UNCOVER-3 and IXORA-S
    Bagel, Jerry
    Gottlieb, Alice B.
    Burge, Russel
    See, Kyoungah
    Garrelts, Alyssa
    McKean-Matthews, Missy
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB82 - AB82
12345